Key Takeaways
- Bayer’s pharma commercialization head Christine Roth is optimistic about revenue growth in 2025 based on sales gains for newer products in 2024 as well as new indications and launches this year.
Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science...